Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity
Daniel M. Harrison(University of Maryland, Baltimore), Peter C.M. van Zijl(Kennedy Krieger Institute), Craig Jones(Johns Hopkins University), Peter A. Calabresi(Johns Hopkins University), Xu Li(Kennedy Krieger Institute), H. Liu(Kennedy Krieger Institute), Brian Caffo(Johns Hopkins University)
Cited by 93
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
|The Lancet|2011|743
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
|The Lancet Neurology|2017|572
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
|Nature Medicine|2000|515
Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination
|Nature Communications|2019|426